Literature DB >> 17258379

Advances in the treatment of Parkinson's disease.

Neha Singh1, Viness Pillay, Yahya E Choonara.   

Abstract

Parkinson's disease (PD) affects one in every 100 persons above the age of 65 years, making it the second most common neurodegenerative disease after Alzheimer's disease. PD is a disease of the central nervous system that leads to severe difficulties with body motions. The currently available therapies aim to improve the functional capacity of the patient for as long as possible; however they do not modify the progression of the neurodegenerative process. The need for newer and more effective agents is consequently receiving a great deal of attention and consequently being subjected to extensive research. This review concisely compiles the limitations of currently available therapies and the most recent research regarding neuroprotective agents, antioxidants, stem cell research, vaccines and various surgical techniques available and being developed for the management of PD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17258379     DOI: 10.1016/j.pneurobio.2006.11.009

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  62 in total

1.  α6ß2* and α4ß2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease.

Authors:  Xiomara A Perez; Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  Mol Pharmacol       Date:  2010-08-23       Impact factor: 4.436

2.  Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates.

Authors:  Xiomara A Perez; Neeraja Parameswaran; Luping Z Huang; Kathryn T O'Leary; Maryka Quik
Journal:  J Neurochem       Date:  2008-02-01       Impact factor: 5.372

3.  Methylphenidate : a treatment for Parkinson's disease?

Authors:  David Devos; Caroline Moreau; Arnaud Delval; Kathy Dujardin; Luc Defebvre; Regis Bordet
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

Review 4.  Uptake and metabolism of iron oxide nanoparticles in brain cells.

Authors:  Charlotte Petters; Ellen Irrsack; Michael Koch; Ralf Dringen
Journal:  Neurochem Res       Date:  2014-07-11       Impact factor: 3.996

Review 5.  Stem cell therapies in age-related neurodegenerative diseases and stroke.

Authors:  Yuan Wang; Xunming Ji; Rehana K Leak; Fenghua Chen; Guodong Cao
Journal:  Ageing Res Rev       Date:  2016-11-19       Impact factor: 10.895

6.  Effect of chronic N-acetyl cysteine administration on oxidative status in the presence and absence of induced oxidative stress in rat striatum.

Authors:  Brian H Harvey; Charise Joubert; Jan L du Preez; Michael Berk
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

Review 7.  Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration?

Authors:  Fábio G Teixeira; Miguel M Carvalho; Nuno Sousa; António J Salgado
Journal:  Cell Mol Life Sci       Date:  2013-03-01       Impact factor: 9.261

8.  Nicotinic Receptors: Role in Addiction and Other Disorders of the Brain.

Authors:  Geeta Sharma; Sukumar Vijayaraghavan
Journal:  Subst Abuse       Date:  2008-11-11

Review 9.  Redox imbalance in Parkinson's disease.

Authors:  Shankar J Chinta; Julie K Andersen
Journal:  Biochim Biophys Acta       Date:  2008-03-04

10.  Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function.

Authors:  Xiomara A Perez; Tanuja Bordia; J Michael McIntosh; Sharon R Grady; Maryka Quik
Journal:  Mol Pharmacol       Date:  2008-06-26       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.